



Bloom Burton & Co.
Healthcare Investor Conference
May 1 - 2, 2017

We gratefully acknowledge the support of our sponsors

BAKER & MCKENZIE

mccarthy
tetrault

Berkley
CANADA
a W.R. Berkley Company

NORTON ROSE FULBRIGHT

Blakes

RICHARDSON GMP

ROSEMARY HORWOOD WEALTH

BLG
Borden Ladner Gervais

TORYS
LLP

Deloitte.

TROUTMAN SANDERS

EY
Building a better
working world

W&R
Wilson Sonsini Goodrich & Rosati
PROFESSIONAL CORPORATION

JLT

Zeifmans
Ideas with impact

Johnson & Johnson INNOVATION | **JLABS**

TMX | Toronto Stock Exchange | TSX Venture Exchange | TSX Private Markets

Welcome to BBHIC 2017

Bloom Burton & Co. exists to accelerate returns in healthcare for both companies and investors, and there is no greater expression of this than our conference, which has grown tremendously over the past six years.

For Canadian healthcare companies and investors, 2017 thus far has followed the tone and trajectory of the final 10 months of 2016: the sector is mounting a gradual overall recovery from the sharp sell-off and reset that started in mid-2015 and ended in early 2016. South of the border, the sector's bounce off the bottom has been tentative compared to the 7-year rocket ride up that followed the global financial crisis. Pressure on drug pricing and the new administration's anticipated moves on health insurance coverage and basic science funding, along with slowing growth of large cap leaders in the sector, have created an uncertain environment in which a rising tide is not lifting all boats. However, successes continue to be rewarded if not already priced in. In Canada, we point to Aurinia's positive 48-week phase 2b data for voclosporin in lupus nephritis; Theratechnologies' positive phase 3 secondary endpoints for ibalizumab in multi-drug resistant HIV; and CRH Medical's continued execution of its roll-up strategy in the colonoscopy anesthesia space. Innovation in biotech continues at break-neck speed, and small companies remain an essential source of new products for multi-nationals, with M&A often providing accelerated and outsized returns for investors in the high risk/high reward biotech (we highlight Cynapsus Therapeutics). The sector has seen robust financing activity, including the IPO of Zymeworks, and the deployment of significant venture, private and public market capital. It remains a "stock picker's" market in which individual companies can certainly succeed, despite the uncertain macro environment. This conference is a great place for investors to uncover the future winners.

Bloom Burton continues to grow. We have expanded the number of professionals at our firm to well over twenty, and we have served even more companies and investor clients through our capital raising, M&A advisory, equity research, scientific consulting and portfolio management work. The exciting companies we have created and incubated, including Triumvira Immunologics, Appili Therapeutics and Grey Wolf Animal Health will once again present at the conference. We are also launching the Bloom Burton Award Gala on September 14, 2017, which each year will honour the most important contributor to the Canadian healthcare sector.


We are humbled to serve our industry and so proud of our talented team, who work with immense dedication to serve our clients. We strive to produce exceptional deliverables and outcomes and we are here for you as you meet and plan for the success of the healthcare sector in Canada.

Have a wonderful conference!

Brian and Jolyon

 @bloomburton

#BBHIC2017

 Bloom Burton & Co.



Agenda - May 1, 2017

8:30

Breakfast

TSX Market Opening Ceremony



Toronto Stock Exchange | TSX Venture Exchange | TSX Private Markets

HALL A

- 9:30 Concordia International
- 10:00 Novellion Therapeutics
- 10:30 Pharmascience
- 11:00 Merus Labs
- 11:30 Knight Therapeutics

HALL B

- ESSA Pharma
- Medicenna Therapeutics
- SQI Diagnostics
- Immunovaccine
- BELLUS Health

HALL C

- 7D Surgical
- Opsens
- Titan Medical
- Klox Technologies
- Kardium

12:00

Lunch

Investor Panel
Moderated by:



Brian Bloom

HALL A

- 13:30 Apotex
- 14:00 CannTrust
- 14:30 Medisure
- 15:00 BioSyent
- 15:30 Cardiome Pharma
- 16:00 Intellipharma

HALL B

- Appili Therapeutics
- Resverlogix
- Aptose Biosciences
- Aequus Pharmaceuticals
- Antibe Therapeutics
- Interface Biologics

HALL C

- Synaptive Medical
- Conavi Medical
- Exact Imaging
- Intellijoint Surgical
- Spartan Bioscience
- Perimeter Medical Imaging

17:00

Reception

Agenda - May 2, 2017

8:30

Breakfast

Keynote Address



Ron Cohen

Chairman, Biotechnology Industry Organization; President and CEO, Acorda Therapeutics

HALL A

- 9:30 Revera
- 10:00 CRH Medical
- 10:30 STEMCELL Technologies
- 11:00 Centric Health
- 11:30 Hamilton Thorne

HALL B

- Aquinox Pharmaceuticals
- Trillium Therapeutics
- Arbutus Biopharma
- Xenon Pharmaceuticals
- Aurinia Pharmaceuticals

HALL C

- Newtopia
- Think Research
- QoC Health
- Diagnos
- VanRx Pharmsystems

12:00

Lunch

Keynote Address



Avik Roy

President, Foundation for Research on Equal Opportunity; Managing Partner, Roy Healthcare Research

HALL A

- 13:30 HLS Therapeutics
- 14:00 Theratechnologies
- 14:30 Nuvo Pharmaceuticals
- 15:00 PEDIAPHARM
- 15:30 Crescita Therapeutics
- 16:00 Acerus Pharmaceuticals

HALL B

- Oncolytics Biotech
- Clementia Pharmaceuticals
- Dalcor Pharamaceuticals
- Triumvira Immunologics
- Northern Biologics
- Turnstone Biologics

HALL C

- Searchlight Pharma
- Grey Wolf Animal Health
- Avivagen
- LED Medical Diagnostics
- Induce Biologics
- ChipCare

17:00

Thank you for attending!



Day 1; 9:30
Hall C
Private

7D Surgical is a privately-owned Toronto based company that develops advanced optical technologies and machine vision-based registration algorithms to improve surgical workflow and patient care. 7D Surgical's flagship FDA 510(k)-cleared and Health Canada approved MIGS™ system delivers profound improvement to surgical workflows in spine surgery, providing the promise of similar future advancements in other surgical specialties.



Day 2; 16:00
Hall A
TSX: ASP

Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.

Acerus currently markets two products in Canada: ESTRACE®, a product indicated for the symptomatic relief of menopausal symptoms; and NATESTO™, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. Acerus' pipeline includes two new innovative products: GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic, used in the treatment of atrophic vaginitis, restoration of vaginal flora and treatment of certain vaginal infections; and TEFINA™, a 'use as required' drug development candidate, aimed at addressing a significant unmet need for women with female sexual dysfunction.



Day 1; 15:00
Hall B
TSX-V: AQS

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus' development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.




Day 1; 15:30
Hall B
TSX-V: ATE

Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.

BBHIC

Through the Years



APOTEX

ADVANCING GENERICS

Day 1; 13:30
Hall A
Private

Apotex is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 10,000 employees and estimated sales of approximately \$2 billion. The company's U.S. headquarters is based in Weston, Florida. With its worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. It produces 300 medicines in 4,000 dosages and formats that are exported to 115 countries. Apotex will spend \$2 billion over the next 10 years on research and development.

APPILI

THERAPEUTICS

Day 1; 13:30
Hall B
Private

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including *C. difficile*. Appili's second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as *Klebsiella pneumoniae*. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health.

APTOS E

BIOSCIENCES

Day 1; 14:30
Hall B
TSX: APS
NASDAQ: APTO

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Aquinox

Day 2; 9:30
Hall B
NASDAQ: AQXP

Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.



Day 2; 10:30
Hall B
NASDAQ: ABUS

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Doylestown, PA.



Day 2; 11:30
Hall B
TSX: AUP
NASDAQ: AUPH

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN. The company is headquartered in Victoria, BC and focuses its development efforts globally.

Why Bloom Burton?

The Bloom Burton team has been dedicated exclusively to the healthcare investment industry for more than a decade. Our deep expertise and experience lets our clients achieve a faster path to their monetizing events. The people who work at Bloom Burton have deep knowledge in medicine, science, patent and corporate law, finance and healthcare invention, development and commercialization.

Who We Serve

We serve investors and companies seeking to make meaningful change to the healthcare industry. We identify the most impactful companies for our investor network and we provide tailor-made support solutions for management and Boards of healthcare companies.

Our Methodology

Our expertise and experience is underpinned by a fundamental understanding of the healthcare industry. Our methodology, and all of the services we offer, rest on six key pillars: deeper due diligence, a broader range of investment options, deep knowledge of cross-border rules, relationships with international investors, engagement with the broader healthcare community, and a creative, tenacious, entrepreneurial culture.

Avivagen

Day 2; 14:30
Hall C
TSX-V: VIV

Avivagen Inc. is a life sciences company that has developed a scientifically-proven product for replacing antibiotics in livestock feeds and to otherwise benefit human and animal health. Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) in Ottawa, Ontario and Charlottetown, Prince Edward Island.

BioSyent

Day 1; 15:00
Hall A
TSX-V: RX

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.



Day 1; 11:30
Hall B
TSX: BLU

BELLUS Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes BLU-5937 for chronic cough and KIACTA™ for sarcoidosis. BELLUS Health also has economic interests in several other partnered drug development projects.



Day 1; 14:00
Hall A
Private

Federally licensed and regulated, CannTrust™ brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. CannTrust applies this expertise to produce quality pharmaceutical-grade dried medical cannabis and the only pharmaceutically standardized cannabis oil in the Canadian market. Our state of the art hydroponic facility and in-house laboratory ensures that our discipline practices produce the highest quality, pesticide free products. The healthcare team at CannTrust places patient access as a top priority and ensures that our customers have the support they need when purchasing medical cannabis. Our Customer Care Team of nurses, MD's, and pharmacists are ready to answer your questions and recommend strains to meet your condition.

Our Services

Raising Capital & Financing

From raising public capital to steering seed money to promising new life science ventures, Bloom Burton & Co. connects investors with healthcare businesses poised to create significant value.

M&A Advisory

Our team's experience and fundamental understanding allows us to guide our clients with commercial, scientific and technical due diligence on their M&A opportunities and development strategies.

Equity Research

Our research division covers key Canadian healthcare companies to understand how they operate, recognize their relative strengths and weaknesses, and determine the impact of clinical and commercial developments and competitive events.

Monetization Planning

Our management consulting practice provides capital market advice, plus scientific, clinical and medical insight to help innovative companies position themselves to profit from their good ideas and achieve a monetizing event. We structure our work as either defined projects or long-term arrangements.

Direct Investment

Through our affiliate Bloom Burton Investment Group, we consult with and offer our extensive knowledge and experience in the healthcare industry to Stratigis Capital Advisors Inc., the manager of three investment products, which provide investors the opportunity to invest in diversified portfolios of leading Canadian healthcare companies.

Company Creation

Continuous creation of new, promising healthcare companies is essential for a vibrant healthcare sector. Bloom Burton partners with entrepreneurs and researchers to form and incubate new companies, in exchange for a founding equity position, where we leverage all of our services and skills to help them create value rapidly, but efficiently.



Day 1; 15:30
Hall A
TSX: COM
NASDAQ: CRME

Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies that will improve the quality of life and health of patients suffering from disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS® (vernakalant IV), approved in Europe, Canada, and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, on behalf of their partner Amomed in select European markets. Cardiome has also licensed: XYDALBATM (dalbavancin hydrochloride), a second generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults for select European and Middle Eastern nations and Canada from Allergan; and TREVYENT®, a development stage drug device combination that is under development for Pulmonary Arterial Hypertension for Europe, the Middle East and for Canadian markets from SteadyMed Therapeutics.



Day 2; 11:00
Hall A
TSX: CHH

Centric Health's vision is to be Canada's most respected and recognized provider in the independent healthcare sectors in which it operates, world renowned for delivering the highest levels of quality care and outcomes, innovative solutions and value to patients, clients and stakeholders. To this end, Centric Health primarily focuses on two core healthcare businesses:

The Specialty Pharmacy division is a "Patient First" model composed of a growing national network of fulfilment centres that deliver high-volume solutions for the cost effective supply of chronic medication and other specialty clinical care services, serving more than 29,000 residents in over 425 seniors communities (long term care facilities, retirement homes and assisted living facilities) nationally. The Specialty Pharmacy division also provides pharmaceutical dispensing services for employees insured by corporate health plans.

The Surgical & Medical Centres division is Canada's largest independent surgical provider operating five facilities across four provinces. It serves a diversified customer base with private paid non-insured surgeries and diagnostics, government outsourcing of insured surgeries and diagnostics and other procedures funded by third-party payors (including Workers Compensation) and is the proud owner of Canada's first Centre of Excellence in Metabolic and Bariatric Surgery.



Day 2; 16:00
Hall C
Private

Leveraging technology developed at the University of Toronto, ChipCare is a point-of-care (POC) diagnostics company that will bring lifesaving diagnostics to the hardest-to-reach populations. The ChipCare PAX (Polyvalent Analyzer) is a portable, easy-to-used multiplex reader that provides lab-quality results in as little as 15 minutes employing low-cost microfluidic disposable cartridges.



Day 2; 14:00
Hall B
Private

Clementia is a clinical stage biopharmaceutical company committed to delivering treatments to people who have none. The company is developing its lead candidate palovarotene, a novel RAR γ agonist, to treat fibrodysplasia ossificans progressiva (FOP) and other diseases. Palovarotene is a retinoic acid receptor gamma agonist (RAR γ) being investigated as a treatment for FOP. Preclinical studies in mouse models of FOP demonstrated that palovarotene blocked both injury-induced and spontaneous heterotopic ossification, maintained mobility, and restored skeletal growth. Palovarotene received Fast Track designation from the U.S. Food and Drug Administration (FDA) and orphan designations for the treatment of FOP from both the FDA and the European Medicines Agency (EMA).



Day 1; 14:00
Hall C
Private

Conavi Medical Inc. develops, manufactures, sells and supports technologies to help guide minimally invasive procedures. It is commercializing technologies initially invented at Sunnybrook Research Institute in Toronto. Conavi employs over 35 highly qualified individuals at our 12,000 square foot ISO-13485 certified facility in Toronto. The company's focus is on providing innovative image guidance technologies for minimally invasive procedures, with an initial emphasis on cardiovascular procedures.



Day 1; 9:30
Hall A
TSX: CXR
NASDAQ: CXRX

Concordia is a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products. The Company has an international footprint with sales in more than 90 countries, and has a diversified portfolio of more than 200 established, off-patent products. Concordia also markets orphan drugs through its Orphan Drugs Division, consisting of Photofrin[®] for the treatment of certain rare forms of cancer.

Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.



Day 2; 15:30
Hall A
TSX: CTX

Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita's board of directors and management team have demonstrated success in building Crescita's predecessor company, Nuvo Research Inc., including developing multiple drugs that are now approved and commercialized and negotiating multiple licensing transactions.



Day 2; 10:00
Hall A
TSX: CRH
NYSE: CRHM

CRH Medical Corporation is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. The CRH O'Regan System is a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. CRH distributes the O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves. CRH's O'Regan System is currently used in all 48 lower US states.

In 2014, CRH acquired Gastroenterology Anesthesia Associates, LLC ("GAA"), a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures. Since then, CRH has incorporated ten additional acquisitions to its anesthesia business. CRH Anesthesia now services 27 ambulatory surgical centers in seven states and performs approximately 170,000 procedures annually.



Day 2; 14:30
Hall B
Private

DalCor is developing precision treatments by genetically targeting patients that will derive clinical benefits. By integrating clinical and genetic insights, DalCor intends to deliver superior clinical cardiovascular outcomes. The company's first development program, dalcetrapib, is intended to reduce cardiovascular events in a specific genetic subset of patients.

On March 7, DalCor announced it is ahead of its enrollment schedule with the randomization of over 1,000 patients of the expected 5,000 patients planned for the Phase 3 "dal-GenE" clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. Patients have been recruited at 642 hospitals in 30 countries, including the U.S., and on six continents.

DalCor has a worldwide exclusive license for dalcetrapib together with rights to the genetic marker for use with dalcetrapib and is sponsoring the dal-GenE study.

DalCor Pharmaceuticals has offices in Montreal, San Mateo, Calif., Zug, Switzerland and Stockport, U.K.



Day 2; 11:30
Hall C
TSX-V: ADK

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence ("AI") tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC). CARA's Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.



Day 1; 9:30
Hall B
TSX: EPI
NASDAQ: EPIX

ESSA Pharma is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer (“CRPC”) in patients whose disease is progressing despite treatment with current therapies. ESSA believes that its product candidate, EPI-506, can significantly expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies. Specifically, EPI-506 acts by disrupting the androgen receptor (“AR”) signaling pathway, which is the primary pathway that drives prostate cancer growth. EPI-002, the primary metabolite of EPI-506, prevents AR activation by binding selectively to the N-terminal domain (“NTD”) of the AR. A functional NTD is essential for activation of the AR. Blocking the NTD prevents activation of the AR by all of the three known mechanisms of activation. In pre-clinical studies, blocking the NTD has demonstrated the capability to overcome the known AR-dependent mechanisms of CRPC. ESSA was founded in 2009.



Day 1; 14:30
Hall C
Private

Exact Imaging is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists will now be able to visualize areas of interest in the prostate and specifically target biopsies at those areas in addition to performing systematic biopsy protocols. The ExactVu™ micro-ultrasound system has recently been granted regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada license).



Day 2; 14:00
Hall C
Private

Grey Wolf Animal Health is an emerging animal health specialty pharmaceutical startup. Grey Wolf’s vision is to establish and grow itself as a fully integrated Canadian animal health company. Grey Wolf was founded by Canadian veterinarian Dr. Ian Sandler whose unique insights on market needs and gaps in Canada were gained over a two decade career in private practices. Grey Wolf plans to gain market share through careful selection of products that meet the needs of Canadian veterinarians and pet owners. Grey Wolf’s three-pronged product commercialization strategy involves in-licensing/exclusive distribution partnerships with global animal health companies, product development via R&D, and acquisition of companies and assets of strategic value. Grey Wolf is on track to commercialize a portfolio of more than 25 products in five years with revenues of more than \$15M+. GWAH is headquartered in Toronto, Canada and is co-founded with Bloom Burton & Co.



Day 2; 11:30
Hall A
TSX-V: HTL

Hamilton Thorne is a leading world-wide provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne’s laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Its image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields. Hamilton Thorne’s standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics. Hamilton Thorne’s growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Cook Medical, Novartis, Pfizer, and Dow Chemical.



HLS Therapeutics Inc.

HLS Therapeutics Inc. is a specialty pharmaceutical company dedicating itself to acquiring and distributing commercial stage mature, or legacy, branded pharmaceutical drugs for the North American markets. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success. Building on the expertise of our founders, HLS is focused on treatment products for the central nervous system, soon to be followed by specialty products in other therapeutic areas.

Day 2; 13:30
Hall A
Private



Day 1; 11:00
Hall B
TSX: IMV

Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. An investigator-sponsored Phase 2 study is currently assessing the safety and efficacy of DPX-Survivac combined with an approved anti-PD-1 drug in advanced ovarian cancer. The Company is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus.



Day 1; 15:00
Hall C
Private

Intellijoint Surgical® develops and commercializes surgical navigation solutions. Intellijoint's flagship product, intellijoint HIP® provides surgeons with real-time, intraoperative measurements to ensure proper positioning of orthopaedic implants during Total Hip Arthroplasty. Intellijoint is committed to driving clinical results through the development of solutions that are accessible, fast, and easy-to-use. Guided by a scientific advisory board comprised of Dr. Allan Gross, an orthopaedic surgeon at Mount Sinai Hospital, and members, Dr. Javad Parvizi at Thomas Jefferson University Hospital, Dr. Michael Cross at Hospital for Special Surgery, Dr. Wayne Paprosky at Rush University Medical Center, and Dr. Ran Schwarzkopf at NYU School of Medicine, Intellijoint is setting the new standard in miniature 3D surgical navigation.

Intellijoint Surgical is the recipient of the 2015 North American Frost & Sullivan Enabling Technology Leadership Award and the Futurpreneur Shopify True Grit Award 2016.

The logo for Intellipharma features the word "intellipharma" in a teal, lowercase, sans-serif font. To the right of the text is a stylized, metallic-looking swoosh that curves upwards and to the right, ending in a sharp point.

Day 1; 16:00
Hall A
TSX: IPCI
NASDAQ: IPCI

We are a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Our current development effort is increasingly directed towards improved difficult-to-develop controlled-release drugs which follow an NDA 505(b)(2) regulatory pathway. The Company has increased its research and development emphasis towards specialty new product development, facilitated by the 505(b)(2) regulatory pathway, by advancing the product development program for our two lead NDA candidates: Rexista™ and Regabatin™.


Rexista™ is an abuse deterrent oral formulation of extended release oxycodone intended to treat moderate-to-severe pain when a continuous, around the clock opioid analgesic is needed. Rexista™ is bioequivalent to OxyContin® and has no food effect. The formulation has Abuse Deterrent properties intended to present a significant barrier to tampering when subjected to various forms of anticipated physical and chemical manipulation commonly used by abusers. It is also designed to prevent dose dumping when inadvertently co-administered with alcohol. The NDA for Rexista was accepted for review by the FDA in February 2017, and the Company was granted a PDUFA target approval date of September 25, 2017.

Our goal is to leverage our proprietary delivery technologies and abuse deterrent know-how to develop a diversified portfolio of abuse deterrent extended-release opioid analgesics with current cumulative US market value of over \$10 billion that can be filed as NDAs via the 505 (b)(2) pathway. We also identify immediate release drugs on the market and novel compounds whose efficacy and compliance can be improved through controlled-release reformulation and development. Through this latter process, we have identified and added several candidates to our 505 (b) (2) drug development pipeline. Our plan is to out-license sales and marketing activities to established organizations, when it makes economic sense. We expect this strategy to permit us to maximize revenues by leveraging the expertise of organizations with formidable sales and marketing infrastructure in key markets and allow us to focus on our core competencies in pharmaceutical drug development.



Day 2; 15:30
Hall C
Private

Induce Biologics Inc. is a regenerative medicine company based in Toronto, Canada, that is developing bioimplants for bone regeneration. The lead product candidate, URIST™, is a novel implant that contains bone morphogenetic protein (BMP), and a proprietary carrier; this carrier provides a gradual, multi-phasic delivery of BMP. This gradual delivery allows for the use of less BMP compared to current products, making it more cost-effective. Also, since all known BMP adverse events and toxicity issues have been related to higher doses of BMP, the ability to use lower doses provides a potential risk benefit as well.



**INTERFACE
BIOLOGICS**

Day 1; 16:00
Hall B
Private

Interface Biologics (IBI) is an early commercial stage privately held company that develops transformative biomedical polymer technologies that improve the safety and effectiveness of medical devices. IBI's primary technology focus areas are anti-thrombogenic additives that reduce thrombosis in blood contacting medical devices and polymer enabled drug delivery platforms.

BBHIC Keynote Speaker



Ron Cohen, M.D

Ron Cohen, M.D. is President, CEO and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for disorders of the nervous system, including multiple sclerosis, Parkinson's disease and migraine.

Dr. Cohen previously was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses. He is Chair of the Board of the Biotechnology

Innovation Organization (BIO), and a Director on the Board of Directors of VBL Therapeutics. He previously served as a Director on the Board of Dyax Corp. until its acquisition in 2016. He also previously served as Chair of the Emerging Companies Section of the BIO Board and as Director and Chair of the New York Biotechnology Association (NYBA). Dr. Cohen is a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University's Alumni Medal for Distinguished Service.

Acorda Therapeutics has been recognized as one of the Best Companies to Work for in New York State seven years in a row (2011-2017), among the Fortune 100 Best Medium-Size Workplaces the U.S. (2017), and among the Fortune 100 Best Workplaces for Women (2016-2017), Millennials (2017) and Baby Boomers (2017).

Dr. Cohen is a recipient of the NY CEO Lifetime Achievement Award and the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region. He was named Neuroinvestment's CEO of the Year and is an inductee of the National Spinal Cord Injury Association's "Spinal Cord Injury Hall of Fame." Dr. Cohen received the Burke Award from Burke Rehabilitation Hospital for his contributions to helping people with disabilities gain independence. He has been recognized by the New York Biotechnology Association as the NYBA "The Cures Start Here" Business Leader of the Year, by the Westchester County Association as its Leadership Award recipient, by Life Science Leader Magazine as True Life Science Leader of the year, and by PharmaVOICE Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry.

Dr. Cohen received his B.A. degree with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed a residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine.

BBHIC Keynote Speaker



Avik Roy

Avik Roy is one of North America's leading experts on healthcare policy. His reform proposal, Transcending Obamacare: A Patient-Centered Plan for Near-Universal Coverage and Permanent Fiscal Solvency, is one of the plans most influential in Washington as Republicans debate how to replace the Affordable Care Act.

Mr. Roy has advised a number of the 2016 presidential candidates on healthcare and other areas of public policy, including Marco Rubio and Rick Perry. In 2012, Mr. Roy served as healthcare policy advisor to Mitt Romney; in that role, he helped develop Romney's agenda on healthcare and entitlement reform for the 2012 presidential campaign. He also served on Romney's presidential transition team, in which capacity he was responsible for recommending candidates for the major healthcare positions in the federal government, including at HHS, CMS, and the FDA.

Mr. Roy is the President of the Foundation for Research on Equal Opportunity (FREOPP.org) and the Managing Partner at Roy Healthcare Research, LLC, which provides proprietary healthcare investment and policy research to institutional investors and stakeholders. Roy's work has been praised widely on both the right and the left. National Review has called him one of America's "sharpest policy minds," while the New York Times' Paul Krugman described him as man of "personal and moral courage."

Roy's writing has also appeared in The Wall Street Journal, The New York Times, The Washington Post, USA Today, The Atlantic, National Review, The Weekly Standard, and National Affairs, among other publications.

He is a frequent guest on television news programs, including appearances on Fox News, Fox Business, CNN, NBC, MSNBC, CNBC, Bloomberg, CBS, PBS, and HBO. He serves on the advisory board of the National Institute for Health Care Management, is a Senior Advisor to the Bipartisan Policy Center, and co-chaired the Fixing Veterans Health Care Policy Taskforce.

From 2011 to 2016, Mr. Roy was a senior fellow at the Manhattan Institute for Policy Research, where he published research on healthcare policy, on topics such as the Affordable Care Act, Medicare, Medicaid, and FDA reform. He is the author of "The Apothecary," an influential blog on healthcare policy at Forbes, where Roy also serves as Opinion Editor.

Prior to his career in healthcare policy, Mr. Roy spent a dozen years on the Wall Street buy side as a health care analyst and portfolio manager, at institutions such as Bain Capital and J.P. Morgan.



Day 1; 11:30
Hall C
Private

Kardium is a technology pioneer working to advance medical device technology in the diagnosis and treatment of atrial fibrillation.

Kardium was founded in 2007 and has built an outstanding team with a track record of excellence in medicine, business, and engineering. We have hired the best engineers, medical researchers, and production staff and have been working with a team of top medical advisors to develop the Globe mapping and ablation system. The Globe system has been entirely developed by the team at Kardium and provides a complete system to assist in the diagnosis and treatment of atrial fibrillation.

Kardium is based in greater Vancouver, Canada, and has consistently ranked as one of the top companies to work for in British Columbia.



Day 1; 11:00
Hall C
Private

Klox is a specialty pharmaceutical company focused on developing and commercializing products based on its proprietary BioPhotonic technology platform to address skin and soft tissue disorders. Klox is advancing its programs as part of its multiple franchises focusing on indications across Dermatology, Wound Care, and Oral Health.



Day 1; 11:30
Hall A
TSX: GUD

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. Knight conducts late-stage clinical development on low risk, low expense product opportunities. All of Knight's products are sourced through partnerships.



See the
difference

Day 2; 15:00
Hall C
TSX-V: LMD

Founded in 2003 and headquartered in Vancouver, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc., LED Dental Ltd and Apteryx, Inc. provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio. The Company is currently listed on the TSX-V under the symbol LMD, the OTCQX under the symbol LEDIF, as well as the Frankfurt Stock Exchange under the symbol LME.



Day 1; 10:00
Hall B
TSX-V: MDNA

Medicenna is a publicly listed (TSXV: "MDNA") clinical stage immunology company developing novel, highly selective engineered versions of IL-2, IL-4 and IL-13 cytokines called Superkines™ and first in class Empowered Cytokines™ (ECs). Medicenna is specifically targeting the Interleukin-4 Receptor, which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna's lead IL-4EC, MDNA55, is enrolling patients in a Phase 2b clinical trial for recurrent glioblastoma (rGB), the most aggressive and common form of brain cancer. MDNA55 has completed three clinical trials in 66 patients with rGB, demonstrated promising efficacy and obtained Fast-Track Designation from the USFDA and Orphan Drug status from the USFDA and EMA. Unlike most other cancer therapies, Medicenna's IL-4 ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.



Day 1; 14:30
Hall A
TSX-V: MPH

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc.



Day 1; 11:00
Hall A
TSX: MSL
NASDAQ: MSLI

Merus Labs is a specialty pharmaceutical company focused on acquiring and optimizing established and growth products. The Merus Labs strategy is driven by an entrepreneurial spirit, coupled with a highly disciplined approach. This allows Merus Labs to acquire and optimize legacy pharmaceuticals and new specialty medicines in a number of therapeutic categories. The Company leverages its expertise and commercial platform to deliver value in Europe, Canada and select other markets including Australia, South Korea and Mexico.



Day 2; 9:30
Hall C
Private

Newtopia is a personalized health company leveraging genetic testing and the latest engagement science to inspire individuals to make healthy lifestyle decisions. Newtopia's patented enterprise health engagement platform combines personality-matched coaching with mobile social health communities and genetically tailored health products to keep clients motivated and on track. Newtopia is partnering with insurers, employers and brands to offer disease prevention and management programs to risk-assessed individuals that deliver proven sustainable outcomes, quantifiable cost savings and a substantive ROI. Newtopia's programs and products are guideline and evidence-based and are available across the United States and Canada.



Day 2; 15:30
Hall B
Private

Northern Biologics was launched in June 2014 by Blueline Bioscience, a Canadian biotechnology incubator backed by venture capital firm Versant Ventures, in partnership with the University of Toronto and University Health Network's Princess Margaret Cancer Centre. Headquartered in the MaRS Discovery District of Toronto, the company is developing a portfolio of antibody-based therapeutics for oncology and fibrosis.



Day 2; 14:30
Hall A
TSX: NRI

Nuvo (TSX:NRI) is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. Nuvo has three commercial products that are available in a number of countries; Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch. Pennsaid 2% is sold in the U.S. by Horizon Pharma plc (NASDAQ:HZNP), is approved for sale, but has not yet been commercially launched, in Russia and is available for partnering in certain other territories around the world. Nuvo manufactures Pennsaid for the global market and Pennsaid 2% for the U.S. market at its FDA, Health Canada and E.U. approved manufacturing facility in Varennes, Québec.



Day 1; 10:00
Hall A
TSX: NVLN
NASDAQ: NVLN

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc. (Aegerion), which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.



Day 2; 13:30
Hall B
TSX: ONC

Oncolytics is a biotechnology company developing REOLYSIN®, an immuno-oncology viral-agent, as a potential treatment for a variety of tumor types. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning its first registration study in breast cancer, as well as studies in combination with checkpoint inhibitors and IMiD/targeted therapies in solid and hematological malignancies.



Day 1; 10:00
Hall C
TSX: OPS

Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.



Day 2; 15:00
Hall A
TSX-V: PDP

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; EpiCeram®, a non-steroid emulsion for eczema; naproxen suspension, indicated to treat pain and inflammation due to various conditions, including Juvenile Idiopathic Arthritis; Rupall™, an innovative new allergy medication with a unique mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is under review with Health Canada.



Day 1; 16:00
Hall C
Private

Perimeter Medical Imaging develops, patents and commercializes advanced surgical imaging tools that allow surgeons, radiologists and pathologists to better assess microscopic tissue structures during the surgical procedure. Perimeter's OTIS™ is the only solution that provides clinicians with an ultra-high resolution image of the entire surface of the removed tissue specimen, providing accurate information in real time, enabling better decisions and ultimately reducing the need for follow-on second surgeries. Perimeter is a privately owned Canadian company.



Day 1; 10:30
Hall A
Private

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with over 1500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 57th among Canada's top 100 R&D investors with over \$44 million invested in 2015, Pharmascience Inc. is the 10th largest pharmaceutical company in Canada.

Pharmascience Inc. has strong long-standing philanthropic ties with its communities, both locally and internationally. For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as the partner of choice to increase access to medicine. Pharmascience's total donations of essential medicine, is close to \$67 million. Pharmascience Inc. is a leading manufacturer and marketer of prescription; generic, over-the-counter (OTC), and behind-the-counter products as well as Food and Drug Administration (FDA) approved Canadian-made injectables. Pharmascience Inc. commercializes nearly 400 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.



Day 2; 10:30
Hall C
Private

QoC Health is a patient health care focused technology company working to improve the relationship between patients, and healthcare service providers leveraging emerging technologies. QoC Health enables patient centered care with mobile solutions, new service delivery models, and cloud computing. QoC has developed a healthcare API (or digital spine) on which health tools are added. So far, three tools are on the market in the areas of post-surgery discharge monitoring, transitions in care, and decision aids.



Day 1; 14:00
Hall B
TSX: RVX

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).



Day 2; 9:30
Hall A
Private

Revera is a leading owner, operator and investor in the senior living sector committed to helping older adults live life to the fullest. Through its portfolio of partnerships, Revera owns or operates more than 500 properties across Canada, the United States and the United Kingdom, offering seniors' apartments, independent living, assisted living, memory care and long term care.

Revera's vision is to celebrate the ageless spirit of people. Through a strategic focus on growth, innovation and leadership, the company strives to improve the aging experience of people in its communities.



Day 2; 13:30
Hall C
Private

Searchlight Pharma is a Canadian-based specialty healthcare company dedicated to improving human health and wellness through the acquisition, commercialization, and focused development of unique healthcare products. We have a proven ability to identify exceptional products, outstanding regulatory and reimbursement expertise and a flexible sales and marketing model. Our expertise supports wide-ranging domestic and international interests and a strong, diverse product list and pipeline.



We are proud to announce

THE INAUGURAL BLOOM BURTON AWARD GALA

September 14, 2017
The Four Seasons Hotel, Toronto

To celebrate the most
extraordinary contribution to the
Canadian healthcare sector

About the award

Bloom Burton & Co. (“Bloom Burton”), is thrilled to introduce the inaugural Bloom Burton Award Gala that will be held at the Four Seasons Hotel in Toronto, Ontario, Canada on September 14, 2017.

Bestowed annually, the Bloom Burton Award will honour an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest impact in Canada’s innovative healthcare industry. Nominees will be accepted from the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, healthcare services or healthcare IT sectors, and from all therapeutic indications and stages of development.

The Bloom Burton Award winner will be chosen by an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism. The panel includes:

- Karen Bernstein, Co-Founder and Chairman, BioCentury Inc.
- Terrence Connolly, Executive Director, Global Alliances and Business Development, Celgene Corporation
- Carl Gordon, Partner and Co-Head of Global Private Equity, OrbiMed Advisors
- Andrew Hack, Chief Financial Officer, Editas Medicine
- Oleg Nodelman, Founder and Managing Director, EcoR1 Capital
- Melinda Richter, Head of Johnson & Johnson Innovation, JLABS
- Avik Roy, Opinion Editor, Forbes; President, The Foundation for Research and Equal Opportunity

All finalists, along with their family and friends, will be invited to and celebrated at the Bloom Burton Award Gala on September 14, 2017. The winner will receive a \$50,000 cash prize, while the other two finalists will each receive \$25,000. A limited number of tickets are available for industry sponsors and individuals.

Brian Bloom, President of Bloom Burton & Co. commented, “It’s time to celebrate those who advance medical science, attract and provide risk capital, launch new products and companies on the world stage or announce significant monetization events. The Bloom Burton Award will celebrate today’s finest, who have made a significant impact – and there will be recognition for this contribution in the year it was achieved.”





Day 1; 15:30
Hall C
Private

Spartan Bioscience's mission is to bring the power of DNA testing to everyone. Spartan's molecular diagnostics platform fully integrates DNA collection, extraction, and analysis in a device that fits in the palm of your hand. Spartan's sample-to-result technology enables unprecedented portability and convenience in applications such as infectious disease, pharmacogenetics, and food and water safety testing.



Day 2; 10:30
Hall A
Private

As Scientists Helping Scientists, STEMCELL Technologies is committed to providing high-quality cell culture media, cell isolation products, accessory tools and educational services for life science research. Driven by science and a passion for quality, STEMCELL provides over 2500 products to more than 90 countries worldwide.



Day 1; 10:30
Hall B
TSX-V: SQD

SQI Diagnostics is the life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality.



Day 1; 13:30
Hall C
Private

Synaptive Medical Inc., a Toronto-based medical device and technology company, collaborates with leading clinicians and healthcare systems to cross traditional barriers and enable continuous improvement in care delivery, in and beyond the operating room. Their integrated BrightMatter™ solutions, which include surgical planning, navigation and visualization, robotics and an integrated informatics platform, are designed and manufactured to give clinicians the information they need to ensure the best possible outcomes for patients.



Day 2; 14:00
Hall A
TSX: TH

Theratechnologies is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients.



Day 2; 10:00
Hall C
Private

Think Research Corporation (TRC) was founded in 2006 by Dr. Chris O'Connor, a practicing critical care physician at Trillium Health Centre. Since our founding, TRC has become the leading provider of digital order sets and clinical decision support tools in Canada. Our order sets and other clinical decision support tools are being used in more than 350 health care facilities across Canada, including province-wide implementations throughout Ontario, Saskatchewan, Prince Edward Island and Newfoundland & Labrador. Our clinical decision support tools are also being used internationally in the United States and Europe.



Day 1; 10:30
Hall C
TSX: TMD

Titan Medical Inc. is focused on the design and development through the planned commercialization of a robotic surgical system for use in MIS. The Company's SPORT Surgical System, currently under development, includes a surgeon-controlled robotic platform that features multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and provides a 3D high-definition endoscopic view inside a patient's body. The SPORT Surgical System is designed to enable surgeons to perform a broad set of general abdominal, gynecologic and urologic procedures.



Day 2; 10:00
Hall B
TSX: TRIL
NASDAQ: TRIL

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing in advanced hematologic malignancies, and a second Phase 1 trial is underway in solid tumors (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.



Day 2; 15:00
Hall B
Private

Triumvira Immunologics Inc. is a biotechnology company developing a novel platform for engineering T cells to attack cancers. Triumvira's innovative and proprietary technology for reprogramming T cells, called the T Cell-Antigen Coupler (or TAC), may possess advantages over other approaches to engineered T cells owing to the distinct biology of TAC-T cells. In solid tumor models, TAC-T cells outperform Chimeric Antigen Receptor (CAR)-T cells, showing better efficacy and markedly improved on- and off-tumor toxicity that correlates with a modulated cytokine secretion profile. Triumvira has licensed the TAC technology from McMaster University in Hamilton, Ontario and intends to begin human testing of TAC T cells in 2018.



Day 2; 16:00
Hall B
Private

Turnstone Biologics Inc. is a biotechnology company focused on developing novel oncolytic viral immunotherapies for cancer. Turnstone's therapeutic platform is a first-in-class tumor-targeted oncolytic vaccine that combines potent tumor-killing effects of oncolytic viruses with the benefits of a cancer vaccine that harnesses the patient's own immune system to fight disease in a sustainable manner. The Company's platform leverages the innovations and expertise of its renowned founding scientists, Drs. John Bell, Brian Lichty and David Stojdl. Turnstone also is developing additional oncolytic virus strategies and immunotherapy combination treatments.



Pharmasystems Inc.

Day 2; 11:30
Hall C
Private

Vanrx Pharmasystems makes the most technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies.



Day 2; 11:00
Hall B
NASDAQ: XENE

Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own and for larger market indications that the company intends to partner with global pharmaceutical companies. Xenon has built a core enabling discovery platform, referred to as Extreme Genetics, for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Xenon's Extreme Genetics platform has yielded the first approved gene therapy product in the European Union and a broad development pipeline and multiple pharmaceutical partnerships, including with Teva and Genentech.

Bloom Burton & Co.

Bloom Burton & Co. exists to
Accelerate Returns in Healthcare

The goal of all investors, companies and organizations is to achieve a monetizing event, such as the ability to raise capital, perform meaningful research and development, license or commercialize products, reach profitability or execute a strategic transaction.

The people who work at Bloom Burton have deep knowledge in medicine, science, patent and corporate law, finance and healthcare invention, development and commercialization.

The Bloom Burton team has been dedicated exclusively to the healthcare investment industry for more than a decade and, as a result of our deep expertise and experience, our clients achieve a faster path to their monetizing events.

Bloom Burton works with institutional and individual investors looking to invest in the healthcare sector. We also work with healthcare companies and organizations of all sizes and stages of development, who seek advice and capital.

As a result of our expertise and experience in healthcare, we have developed a disciplined methodology for helping companies grow faster. Our methodology, and all of the services we offer, rest on six key pillars: deeper due diligence, a broader range of investment options, greater understanding of cross-border rules, relationships with international healthcare-specialized investors, engagement with the broader healthcare community, and a creative, tenacious, entrepreneurial culture.

Our Services

Our services help identify, cultivate and create investment opportunities in the healthcare sector, on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, life science tools, animal health, nutrition and wellness.

Our six business services work cohesively to accelerate monetization for both company and investor clients:



Raising Capital
& Financing



M&A
Advisory



Equity
Research



Monetization
Planning



Direct
Investment



Company
Creation

Raising Capital & Financing

Sourcing capital to fund healthcare opportunities

From steering seed money to promising new life science ventures to facilitating private financing or raising public capital, Bloom Burton & Co. connects investors with attractive healthcare businesses poised for growth and profit.

As investment bankers, we nurture relationships between worthy companies and engaged investors who want to provide funding and participate in the growth of the healthcare sector.



Raise funding through a range of securities

We deal in the full range of securities to suit the capital requirements, or risk and return objectives, of companies and investors, from equity and debt issues to private placements or participating in selling groups of public offerings.



Garner attention of top fund managers

Our firm's unique professional relationships with international healthcare-specialized private and public fund managers has helped attract capital from around the world to Bloom Burton's issuer clients.



Private Placement
March 2017

\$14,000,000



Private Placement
February 2017

\$25,000,000



Private Placement
February 2017

\$14,400,000



Bought Deal
December 2016

\$330,050,000



Series A Financing
October 2016

\$10,000,000



Private Placement
July 2016

\$107,000,000



Private Placement
January 2016

USD \$15,000,000



HLS Therapeutics Inc.

Private Placement
August 2015

USD \$200,000,000

M&A Advisory

Enabling monetization through strategic transactions

The mergers and acquisitions advisory capability at Bloom Burton guides clients to conceptualize, structure and execute transactions to maximize returns and company performance.

Our team's professional expertise in healthcare and intellectual property also allows us to guide our clients with scientific and technical due diligence on their M&A opportunities and development strategies.

Guiding a broad range of M&A-type transactions

- Strategic Acquisitions
- Sales & Divestitures
- Spinoffs & Splitoffs
- Strategic Partnerships
- Reorganization & Restructuring
- Leveraged Buyouts
- Takeover Defenses & Proxy Contests
- Special Committee Assignments
- Fairness/Valuation Opinions



M&A Transaction
February 2017
USD \$10,250,000



M&A Transaction
February 2016
USD \$148,000,000



M&A Transaction
November 2015
\$47,000,000



M&A Transaction
June 2015
\$25,000,000



M&A Transaction
December 2014
USD \$73,200,000



M&A Transaction
October 2014
USD \$45,000,000



M&A Transaction
September 2013
\$357,000,000



M&A Transaction
December 2012
USD \$510,000,000

Equity Research

Influential opinions and insights on companies

Our equity analysts ask the right questions, dig deeper for answers and find details others miss. Our research division covers key Canadian healthcare companies to understand how they operate, recognize their relative strengths and weaknesses, and determine the impact of clinical and commercial developments and competitive events.

Specialized equity research that gets attention

Our analysts make influential buy, sell and hold recommendations in healthcare and biotechnology, gather industry knowledge, and provide insightful market intelligence to help guide our investor clients.

Charting what's new in biotech: Our Canadian Healthcare Roadmap Publication

Our Canadian Healthcare Roadmap report, published twice a year, is essential reading for institutional investors to track drugs and medical products in development or being commercialized by public healthcare companies, as well as milestones that could impact share performance.

Distribution of healthcare research

Bloom Burton's research products are disseminated simultaneously to all our customers who are authorised to receive them. Request to be added to Bloom Burton's equity research distribution list. Email Brian Bloom at bbloom@bloomburton.com.

Research Coverage

- Specialty Pharmaceuticals
- Healthcare Services
- Biotechnology

Specialty Pharmaceuticals



Healthcare Services



Biotechnology



Monetization Planning

Helping realize the value of innovations

Understanding the business opportunities to bring healthcare advances to market, and how to successfully utilize them, are key to any company's commercial and financial success. It is also key to investor returns.

Our management consulting practice provides capital market advice, plus scientific, clinical and medical insight to help innovative companies position themselves to profit from their good ideas and achieve a monetizing event. We structure our work as either defined projects or long-term arrangements.

Why companies and investors come to us

We speak with large companies and investors every day, and we know what they are looking for. We are therefore the ideal group to help our companies plan their capital market strategies, investigate the relevance of new biological pathways, and consider new therapeutic indications and clinical designs, catalogue and diligence new products or companies for acquisition.



Monetization Planning
September 2016



Monetization Planning
September 2016



Scientific Advisory
January 2015



Scientific Advisory
January 2015



Valuation Opinion
October 2015



Strategic Advisory
October 2014



Capital Markets
& Scientific Advisory
March 2014



Scientific Advisory
September 2013

Direct Investment

Maximizing opportunities in healthcare investing

Through our affiliate Bloom Burton Investment Group, we consult with and offer our extensive knowledge and experience in the healthcare industry to Stratigis Capital Advisors Inc., the manager of the following three investment products which provide investors the opportunity to invest in a diversified portfolio of healthcare companies:

Bloom Burton Canadian Healthcare Fund LP

The Bloom Burton Canadian Healthcare Fund exists to achieve superior returns by investing primarily in equity and equity-linked securities of publicly traded Canadian healthcare and biotechnology companies. The Fund invests in companies of all capitalization sizes with a focus on the biotechnology, emerging pharmaceutical, medical device, diagnostic and healthcare service industries. The manager employs fundamental, bottom-up quantitative analysis and a qualitative research methodology to identify mispriced securities or assets in a market in which Bloom Burton has unique insights, respected experience and long-standing relationships.

Bloom Burton Healthcare Structured Lending Fund I and II LP and Bloom Burton Healthcare Lending Trust

The Bloom Burton Healthcare Structured Lending I and II LP Funds and the Bloom Burton Healthcare Lending Trust exist to achieve superior returns for investors by targeting a specialized niche in the fund market that is overlooked by other lenders. The Fund and the Trust provide debt or debt-like capital to emerging commercial-stage Canadian healthcare companies with assets and cash-flow to support debt, but seeking funding amounts not provided by traditional lenders. The Fund and the Trust invest in both privately held and publicly traded companies using a variety of structures.

For additional information relating to these investment products, please contact Stratigis Capital Advisors Inc. at +1 416 368 6002 or info@stratigis.ca

Company Creation

Establishing new opportunities in healthcare

In very special situations, instead of providing services for cash fees, Bloom Burton partners with entrepreneurs and researchers to form and incubate new companies, in exchange for a founding equity position. Bloom Burton leverages all of its services and skills:

- Advise on the company's corporate and capital structure;
- Catalog and select the best target indications based on commercial, competitive and scientific considerations;
- Design the optimal international patent strategy;
- Design preclinical and clinical programs to produce valuable evidence for financing and partnering;
- Support the optimal regulatory strategy;
- Advise on the identification, license or acquisition of complimentary intellectual property and assets;
- Recruit the best management team and Board to help execute the Company's strategy;
- Create marketing materials to inform, engage and transact with investors and partners;
- Raise seed and subsequent private and public capital; and
- Leverage the entire Bloom Burton platform to increase the exposure of the Company.



Bloom Burton and its network of healthcare industry veterans publish regular pieces on the state of Biotech, Pharma, Med Tech and Healthcare IT in Canada and the US. Here is a selection from the past year:

LOOKING INSIDE THE **BIOTECH** BLACK BOX

A deeper look into various topics of drug development
by Wayne Schnarr.

- Market Exclusivity - Product Life-Cycle Management
- Market Exclusivity - Regulatory Data
- Market Exclusivity - Patents

APOLLO **SHRUGGED** TALES FROM THE CANADIAN PHARMA INDUSTRY

A modern view on drug adherence
by Stephen Nicolle.

- Contradictions in Provincial Pharamacare
- Can Technology Improve Patient Adherence

Q4 SHARE PRICE PERFORMANCE IN THE CANADIAN **PART 2** HEALTHCARE SECTOR

Detailed quarterly reviews of share price performance in the Canadian healthcare industry
by Wayne Schnarr.

GUEST **EDITORIAL**

An invited guest blog on healthcare investment and company growth.

- Beyond Borders: Keeping your business investor friendly
by Mark Smith
- Understanding our Canadian Life Sciences Environment
by Mario Piccinin and Karen Atkinson

To read more, subscribe online at www.bloomburton.com/news

Our People

Executives



Brian Bloom
Co-founder,
Chairman & CEO



Jolyon Burton
Co-founder, President
& Head of Investment
Banking



Armand Balboni JD, PhD
Director, Medical & Legal Due
Diligence Group



David Martin PhD, MBA
Managing Director &
Head of Equity Research



Antonia Borovina PhD
Associate, Equity Research



Prasath Pandurangan MBBS, CFA
Associate, Equity Research

Investment Banking



Shawn Aspden CFA
Managing Director



Michael Pollard MBA, CFA
Vice President,
Investment Banking



John Holyoake DPhil
Vice President,
Investment Banking



Andrew Duckman
Vice President, Corporate
Development



Matthew Johnson MSc
Vice President, Business
Development

Corporate & Business Development



Evelyn Pau PhD
Associate



James Rowland MSc
Associate, Investment Banking



Stephanie Mazzone CPA, CA
Chief Financial Officer



Kari Tavener
Chief Compliance Officer



Erika Agnew
Senior Administrator

Corporate Staff



Claudia Hui PhD
Analyst



Vincent Nadeau PhD
Analyst



Chi Liu
Analyst, Investment Banking



Alycia Gambarotto
Accounting Clerk



Eleanor Ndaiga
Communications Analyst

Notes





bloom burton & co

/accelerating returns in healthcare